Trial Profile
A 48-week, Open-label, 2-arm, Parallel-group, Randomized Exploratory Study to Assess Liver Iron Concentration Measured by FerriScan (R2) Magnetic Resonance Imaging in B-thalassemia Subjects Administered SPD602 (SSP-004184AQ) or Exjade (Deferasirox) for Treatment of Chronic Transfusional Iron Overload
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Deferitazole (Primary) ; Deferasirox
- Indications Haemosiderosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Shire
- 01 Jun 2021 Planned End Date changed from 1 Aug 2015 to 30 Oct 2015.
- 01 Jun 2021 Planned primary completion date changed from 1 Oct 2015 to 30 Oct 2015.
- 01 Jun 2021 Planned initiation date changed from 1 Dec 2013 to 20 Nov 2014.